An open-label, multi-center rollover protocol for patientswho have participated in a Novartis-sponsored ribociclib(LEE011) study and are continuing to benefit fromribociclib as single agent or in combination with otherinvestigational treatments
Phase 1
Recruiting
- Conditions
- Different types of advanced cancerTherapeutic area: Not possible to specify
- Registration Number
- CTIS2024-511125-61-00
- Lead Sponsor
- ovartis Pharma AG
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 4
Inclusion Criteria
Patient is currently enrolled in an eligible Novartis-sponsored ribociclib (LEE011) study and is receiving ribociclib as single agent or in combination with other investigational treatments., Patient is currently deriving clinical benefit from the study treatment, as determined by the investigator., Patient has demonstrated compliance, as assessed by the investigator, with the parent protocol requirements.
Exclusion Criteria
Patients who have permanently discontinued from ribociclib (LEE011) in the parent protocol for any reason, Patients who do not meet parent protocol criteria to continue study treatment.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method